ABT-288

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.
INTRODUCTION ABT-288 is a highly potent histamine-3 receptor antagonist that has demonstrated pro-cognitive effects in… (More)
Is this relevant?
2014
2014
A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.
BACKGROUND ABT-288, a highly selective histamine-3 receptor antagonist, demonstrated efficacy across several preclinical… (More)
Is this relevant?
2014
2014
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
AIMS ABT-288 is a potent and selective H3 receptor antagonist with procognitive effects in several preclinical models. In… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 4
Is this relevant?
2014
2014
A Randomized Study of H 3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer ’ s Dementia 1
Background: ABT-288, a highly selective histamine-3 receptor antagonist, demonstrated efficacy across several preclinical… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
AIM The objective of this work was to characterize the safety, tolerability and pharmacokinetics of ABT-288, a highly selective… (More)
Is this relevant?
2013
2013
Assessment of the abuse liability of ABT-288, a novel histamine H3 receptor antagonist
Histamine H3 receptor antagonists, such as ABT-288, have been shown to possess cognitive-enhancing and wakefulness-promoting… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
Blockade of the histamine H(3) receptor (H(3)R) enhances central neurotransmitter release, making it an attractive target for the… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
2012
2012
Evaluation of the efficacy and safety of the H3 antagonist ABT-288 in mild-to-moderate Alzheimer's disease
 
Is this relevant?
2010
2010
ABT-288, a potent and selective histamine H3 receptor antagonist, facilitates attention and memory in preclinical models
 
Is this relevant?